Health
Targeted therapies developed to reduce lung fibrosis – Medical Xpress
A new treatment option for lung fibrosis is being developed by Purdue University scientists. Lung fibrosis has been a concern for COVID-19 patients.
A new treatment option for lung fibrosis is being developed by Purdue University scientists. Lung fibrosis has been a concern for COVID-19 patients.
People with idiopathic pulmonary fibrosis (IPF) have a life expectancy of less than five years. Fibrotic diseases cause organ failure that lead to about 45% of all deaths in the United States. Existing therapies do little to slow progression.
Now, Philip S. Low, the Purdue Ralph C. Corley Distinguished Professor of Chemistry and Presidential Scholar…
-
Business21 hours agoMacquarie tips 14% upside for this ASX tech stock
-
Noosa News17 hours agoWilliam Robinson dies aged 89
-
Noosa News17 hours agoTwo-time Archibald Prize-winning painter William Robinson has died, aged 89
-
Business21 hours agoWhat to do with these 3 ASX 200 retail shares after strong price runs: experts